134 related articles for article (PubMed ID: 20407895)
1. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
Denton CL; Gustafson DL
Cancer Chemother Pharmacol; 2011 Feb; 67(2):349-60. PubMed ID: 20407895
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
[TBL] [Abstract][Full Text] [Related]
3. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.
Davies BR; Logie A; McKay JS; Martin P; Steele S; Jenkins R; Cockerill M; Cartlidge S; Smith PD
Mol Cancer Ther; 2007 Aug; 6(8):2209-19. PubMed ID: 17699718
[TBL] [Abstract][Full Text] [Related]
4. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
Haass NK; Sproesser K; Nguyen TK; Contractor R; Medina CA; Nathanson KL; Herlyn M; Smalley KS
Clin Cancer Res; 2008 Jan; 14(1):230-9. PubMed ID: 18172275
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.
Huynh H; Soo KC; Chow PK; Tran E
Mol Cancer Ther; 2007 Jan; 6(1):138-46. PubMed ID: 17237274
[TBL] [Abstract][Full Text] [Related]
6. The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.
Shannon AM; Telfer BA; Smith PD; Babur M; Logie A; Wilkinson RW; Debray C; Stratford IJ; Williams KJ; Wedge SR
Clin Cancer Res; 2009 Nov; 15(21):6619-29. PubMed ID: 19843666
[TBL] [Abstract][Full Text] [Related]
7. Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer.
Gao JH; Wang CH; Tong H; Wen SL; Huang ZY; Tang CW
Sci Rep; 2015 Nov; 5():16382. PubMed ID: 26567773
[TBL] [Abstract][Full Text] [Related]
8. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
[TBL] [Abstract][Full Text] [Related]
10. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
[TBL] [Abstract][Full Text] [Related]
11. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.
Kolb EA; Gorlick R; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA
Pediatr Blood Cancer; 2010 Oct; 55(4):668-77. PubMed ID: 20806365
[TBL] [Abstract][Full Text] [Related]
12. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Banerji U; Camidge DR; Verheul HM; Agarwal R; Sarker D; Kaye SB; Desar IM; Timmer-Bonte JN; Eckhardt SG; Lewis KD; Brown KH; Cantarini MV; Morris C; George SM; Smith PD; van Herpen CM
Clin Cancer Res; 2010 Mar; 16(5):1613-23. PubMed ID: 20179232
[TBL] [Abstract][Full Text] [Related]
13. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.
Xu J; Knox JJ; Ibrahimov E; Chen E; Serra S; Tsao M; Cao P; Vines D; Green DE; Metran-Nascente C; McNamara MG; Hedley DW
Clin Cancer Res; 2013 Jan; 19(1):118-27. PubMed ID: 23091117
[TBL] [Abstract][Full Text] [Related]
14. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
[TBL] [Abstract][Full Text] [Related]
15. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
16. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
17. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
Bennouna J; Lang I; Valladares-Ayerbes M; Boer K; Adenis A; Escudero P; Kim TY; Pover GM; Morris CD; Douillard JY
Invest New Drugs; 2011 Oct; 29(5):1021-8. PubMed ID: 20127139
[TBL] [Abstract][Full Text] [Related]
18. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
Yoon J; Koo KH; Choi KY
Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
